{
    "2018-05-01": [
        [
            {
                "time": "2018-09-15",
                "original_text": "U.S. approves Novartis cell therapy for lymphoma",
                "features": {
                    "keywords": [
                        "Novartis",
                        "cell therapy",
                        "lymphoma",
                        "FDA approval"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-05-01",
                "original_text": "Novartis says Kymriah receives second U.S. FDA approval",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Kymriah",
                        "second approval",
                        "FDA"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "Incyte (INCY) Incurs Loss in Q1, Revenues Miss Estimates",
                "features": {
                    "keywords": [
                        "Incyte",
                        "Q1 loss",
                        "revenue miss",
                        "estimates"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-07-12",
                "original_text": "Breakthrough cancer therapy developed at Penn receives 2nd FDA approval",
                "features": {
                    "keywords": [
                        "cancer therapy",
                        "Penn",
                        "2nd FDA approval",
                        "breakthrough"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-08-03",
                "original_text": "Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings",
                "features": {
                    "keywords": [
                        "Karyopharm",
                        "STORM Study",
                        "Inogen",
                        "earnings rally"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-03",
                "original_text": "GlaxoSmithKlineâ€™s Valuation after 1Q18 Earnings",
                "features": {
                    "keywords": [
                        "GlaxoSmithKline",
                        "valuation",
                        "1Q18 earnings"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-24",
                "original_text": "Pfizer tops earnings estimates, driven by sales of pneumonia vaccine Prevnar",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "earnings",
                        "Prevnar",
                        "pneumonia vaccine"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-16",
                "original_text": "Novartis provides update on proposed acquisition of AveXis",
                "features": {
                    "keywords": [
                        "Novartis",
                        "AveXis",
                        "acquisition update"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-30",
                "original_text": "Novartis-AveXis Deal Receives U.S. Regulatory Approval",
                "features": {
                    "keywords": [
                        "Novartis",
                        "AveXis",
                        "deal approval",
                        "regulatory"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}